Repare Therapeutics Inc. announced that the first patient has been dosed in its Phase 1 POLAR clinical trial evaluating RP-3467. RP-3467 is a Polθ ATPase inhibitor, representing Repare’s fourth clinical program.
The POLAR trial is designed as a multicenter, open-label, dose-escalation study to investigate the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of RP-3467. It will be evaluated alone and in combination with the PARP inhibitor, olaparib.
The study is expected to enroll approximately 52 patients with locally advanced or metastatic epithelial ovarian cancer, metastatic breast cancer, metastatic castration-resistant prostate cancer, or pancreatic adenocarcinoma. The primary objectives include assessing safety and tolerability, and defining a preliminary recommended Phase 2 dose.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.